441060-95-3

Usage

Uses

Used in Pharmaceutical Synthesis:
Clofencet is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new medications with potential therapeutic benefits.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, clofencet is used as a research compound to explore its anti-inflammatory and analgesic properties, with the aim of creating new drugs that can effectively treat pain and inflammation.
Used in Organic Synthesis:
The nitrile group present in clofencet makes it a valuable building block in organic synthesis, where it can be used to construct more complex organic molecules for various applications.
Used in Drug Development:
Clofencet is utilized in drug development as a potential candidate for creating new medications, particularly those targeting inflammation and pain management, due to its studied properties.
Used in Chemical Education and Training:
In educational and training settings, clofencet can serve as a practical example of a pharmaceutical intermediate and a compound with potential medicinal applications, aiding in the understanding of chemical synthesis and drug development processes.

InChI:InChI=1/C11H10ClNO2/c1-7(14)10(6-13)9-4-3-8(15-2)5-11(9)12/h3-5,10H,1-2H3

Upstream product

• 141-78-6 ethyl acetate 
• 170737-93-6 2-chloro-4-methoxyphenylacetonitrile 
• 50638-46-5 4-bromo-3-chloroanisole 
• 70807-22-6 3-hydroxycrotononitrile sodium salt 

Downstream Products

• 817636-93-4 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine tosylate 
• 1100592-51-5 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-2,5,6-trimethylpyrazolo[1,5-a]pyrimidin-7-amine 
• 1338727-94-8 5-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-6-methyl-2,3-dihydrofuro[3,2-d]pyrazolo[1,5-a]pyrimidin-9-amine 
• 441060-02-2 (1-ethyl-propyl)-[3-(4-methoxy-2-chlorophenyl)-2-methyl-6,7-dihydro-5H-1,4,8a-triaza-s-indacen-8-yl]-amine 
• 817636-91-2 8-chloro-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine 
• 817636-90-1 8-hydroxy-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine 
• 1338727-99-3 3-[2-chloro-4-(difluoromethoxy)phenyl]-N-(1-ethylpropyl)-2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidin-8-amine 
• 857262-72-7 3-chloro-4-[8-(1-ethylpropylamino)-2-methyl-6,7-dihydro-5H-1,4,8a-triaza-s-indacen-3-yl]-phenol 
• 1338728-00-9 3-(2-chloro-4-methoxyphenyl)-N-(1-ethylpropyl)-2-methyl-6,7-dihydrofuro[2,3-d]pyrazolo[1,5-a]pyrimidin-8-amine 
• 1338727-93-7 3-(2-chloro-4-methoxyphenyl)-2-methyl-6,7-dihydrofuro[2,3-d]pyrazolo[1,5-a]pyrimidin-8-amine 
• 817636-89-8 4-(2-chloro-4-methoxy-phenyl)-5-methyl-1H-pyrazol-3-ylamine 
• 817636-89-8 4-(2-chloro-4-methoxyphenyl)-5-methyl-2H-pyrazol-3-ylamine 

Relevant academic research and scientific papers

6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists

To identify an orally active corticotropin-releasing factor 1 receptor antagonist, a series of 6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives were designed, synthesized and evaluated. An in vitro study followed by in vivo and pharmacokinetic studies of these heterotricyclic compounds led us to the discovery of an orally active CRF1 receptor antagonist. The results of a structure-activity relationship study are presented.

METHANESULFONIC ACID SALT OF PYRAZOLOPYRIMIDINE COMPOUND, CRYSTAL THEREOF, AND PROCESS FOR PRODUCING THE SAME

The present invention relates to 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7 -dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate, a crystal thereof, a process for the preparation thereof, and a process for the preparation o

TRICYCLIC AND HETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT

Tri- heterocyclic compound of formula (I) wherein each of W, X and Y is carbon or nitrogen; each of U and Z is CR2, NR13, nitrogen, oxygen, sulfur etc.; A ring is carbocyclic ring, heterocyclic ring; R1 is alkyl, alkenyl,

The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4- methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: A corticotropin-releasing factor (hCRF1) antagonist

Structure-activity relationship studies led to the discovery of 4-(3- pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]- pyrimidine 11-31 (DMP904), whose pharmacological profile strongly supports the hypothesis that hCRF1 antagonists may be potent anxiolytic drugs. Compound 11-31 (hCRF1 K(i) = 1.0 ± 0.2 nM (n = 8)) was a potent antagonist of hCRF1-coupled adenylate cyclase activity in HEK293 cells (IC50 = 10.0 ± 0.01 nM versus 10 nM r/hCRF, n = 8); α-helical CRF(9-41) had weaker potency (IC50 = 286 ± 63 nM, n = 3). Analogue 11-31 had good oral activity in the rat situational anxiety test; the minimum effective dose for 11-31 was 0.3 mg/kg (po). Maximal efficacy (approximately 57% reduction in latency time in the dark compartment) was observed at this dose. Chlordiazepoxide caused a 72% reduction in latency at 20 mg/kg (po). The literature compound 1 (CP154526-1, 30 mg/kg (po)) was inactive in this test. Compound 11-31 did not inhibit open-field locomotor activity at 10, 30, and 100 mg/kg (po) in rats. In beagle dogs, this compound (5 mg/kg, iv, po) afforded good plasma levels. The key iv pharmacokinetic parameters were t(1/2), CL and V(d,ss) values equal to 46.4 ± 7.6 h, 0.49 ± 0.08 L/kg/h and 23.0 ± 4.2 L/kg, respectively. After oral dosing, the mean C(max), T(max), t(1/2) and bioavailability values were equal to 1260 ± 290 nM, 0.75 ± 0.25 h, 45.1 ± 10.2 h and 33.1%, respectively. The overall rat behavioral profile of this compound suggests that it may be an anxiolytic drug with a low motor side effect liability. (C) 2000 Elsevier Science Ltd.